Baltimore, MD, November 5, 2019 – AccuGenomics Inc., a Wilmington, NC developer of powerful control technology that dramatically improves the accuracy and performance of clinical sequencing tests presented interim data on the performance of their spike-in controls to the AMP Reference Materials Forum as part of the Association of Molecular Pathology Annual Meeting. The data were from the FDA-led SEQC2…
Identification of actionable mutations in circulating tumor DNA (ctDNA) enables gene-targeted therapy of solid tumors based on a simple blood test. NGS methods that attach a unique molecular identifier (UMI) to each DNA molecule control for sequencing technical error and thereby reduce variant allele fraction (VAF) limit of detection (LOD) to <0.01% at a cost of 10-20-fold higher sequencing requirement.…
Patent Issued for Diagnostic Tool to Identify Human Genetic Information – WILMINGTON, NC, December 12, 2018 – AccuGenomics, Inc., a diagnostic company based in Wilmington, NC, is pleased to announce that the United States Patent and Trademark Office (USPTO) has awarded a patent to technology licensed to AccuGenomics. U.S. Patent Number 9,944,973, entitled “Methods for Standardized Sequencing of Nucleic Acids…